Abstracts LBP treatment rates. Wilcoxon signed-rank tests were used to compare study period direct (medical and drug) costs from third-party payer perspective. RESULTS: During the 6-month study period, duloxetine-treated patients vs. controls had signifi cantly lower rates of other pharmacological therapy (34.2% vs. 43.4% narcotic opioids, p 0.004; 30.4% vs. 43.2% NSAIDs, p 0.001; 17.4% vs. 26.2% muscle relaxants, p 0.001; 10.6% vs. 20.4% corticosteroids, p 0.001) and non-invasive therapy (16.4% vs. 35.6% chiropractic therapy, p 0.001; 13.0% vs. 34.2% physical therapy, p 0.001). Duloxetine-treated patients were also signifi cantly less likely to have a back surgery during the study period compared with controls (0.4% vs. 2.0%, respectively; p 0.021). Average 6-month direct costs were not signifi cantly different between duloxetine-treated patients and controls ($3554 vs. $3637, respectively). CONCLUSIONS: Duloxetine treatment in LBP patients vs. other non-surgical treatment was associated with a lower surgery rate as well as reduced rates of other nonsurgical therapies without signifi cant differences in direct costs. (2005)(2006)(2007). We analyzed one-year health care utilization (outpatient, emergency room visits, and hospitalization) and total cost of clotting factor dispensed. Factor cost was estimated using average sales price from Medicare Part B. We further examined the association between these variables and clotting factor infusion strategies (episodic(to treat a bleed) versus prophylactic (administrate multiple times each week)) in patients with severe hemophilia using Chi-square test for categorical variables or Wilcoxon rank-sum test for continuous variables. RESULTS: Fifty percent of patients were adults; Mean age 9.7 4.5 years for children and 33.7 12.5 years for adults. Two-thirds of patients had severe hemophilia. 97% used clotting factor; 68% of severe patients infused prophylactically. 89% reported using health services at least once: 56% had a comprehensive visit(range:0-3); 31% a clinician visit(range:0-14); 23% saw a physical therapist(range:0-21). 19% had emergency room visits and 15% were hospitalized. Mean cost of clotting factor was $208,548(median:$232,831) per patient-year. In patients with severe hemophilia, average number of hospital days/ patient-year was 8(3 for prophylaxis users versus 13 for episodic treatment users, p 0.14). Patients with severe hemophilia were less likely to have an emergency room visit if they were on prophylaxis(13% vs. 25%, p 0.047). Mean factor cost was $281,151 per patient-year(median:$224,856) for patients on prophylaxis versus $15 4,855(median:$126,148) for episodic treatment users(p 0.0001). CONCLUSIONS: This study contributes to the growing evidence that prophylactic infusion of clotting factors, compared to episodic treatment, may be associated with decreased health care utilization, including emergency room visits and hospitalizations. Medicres Oy, Oulu, Finland, 5 Oulu university hospital, Oulu, Finland OBJECTIVES: To describe and measure intravenous patient controlled analgesia (IV-PCA) processes in postoperative pain management in patients with moderate to severe pain in clinical practice that have undergone surgery at the University Hospital Oulu Finland. METHODS: A model was designed and visualized via Swimlane notation. Sub process levels were defi ned as "education", "purchasing/depreciation/maintenance", "procurement", "supply", "application" and "disposal". Based on these sub process levels, data was collected by two research methods, interviews and measurement forms including patient and staff satisfaction questionnaires. RESULTS: Twelve members of Oulu University Hospital personnel with different responsibilities were interviewed to defi ne the roles and activities involved in the entire IV-PCA process. Ten different roles were defi ned with 151 different activities. The involved roles and the duration of each activity in the sub process levels "supply", "application" and "disposal" were measured from 108 consecutive patients with eight different surgery types. The most common surgery types were back surgery and gynecological laparoscopy. The average duration of IV-PCA use per patient was 41 hours and 39 minutes. The staff spent on average 132 minutes in IV-PCA related activities, of which the nurse spent 91%. The average cost, including material and staff, for 24-hour usage of IV-PCA was €122. The patients found the IV-PCA system easy to operate but hindered them in mobility and they were not able to sleep unhindered. According to the staff the IV-PCA system operated error-free and reliably but hindered the mobilization of the patient. CONCLUSIONS: IV-PCA involves many different roles and activities and intertwined sub processes. Therefore the whole system is complex and resource demanding. Comparisons of the results from similar studies at other hospitals will be very useful when trying to optimize the process. . The K-6 assesses the person's non-specifi c psychological distress (higher value means severe mental disability) and the PHQ2 assesses the depression severity. PHQ2 score of 3 was used to screen asthma patient with depression. The impact of obesity on HRQOL was estimated using multivariable regression while controlling for patients' demographic, socio-economic, and co-morbidity variables. Data were analyzed using SAS and STATA. RESULTS: A total of 5339 asthma patients were identifi ed. Overall, HRQOL in obese patients were signifi cantly lower compared to those of normal weight patients (50.7 vs. 41.9 for PCS-12, 49.0 vs. 47.0 for MCS-12, 3.9 vs. 5.3 for K-6, 0.6 vs. 1.1 for PHQ-2). While controlling for the study variables, QOL were worse if patients were obese, older, female, or less educated, as well as have cardiovascular disease. Proportion of patients with PHQ2 score 3 were 10.3% in normal weight and 19.7% in obese patients. CONCLUSIONS: Obesity signifi cantly deteriorates quality of life including both physical and mental components in asthma patients. The national health promotion to control weight needs to be emphasized to increase the benefi cial effects of HRQL in asthma patients. Patients with failed back surgery syndrome (FBSS) and chronic neuropathic pain experience levels of health-related quality of life (HRQoL) that are considerably lower than those reported in other areas of chronic pain. Interventions aimed at reducing pain in FBSS patients are expected to bring considerable HRQoL improvements. Using data from the multinational PROCESS trial, we investigated the longitudinal relationship between generic HRQoL -assessed using two instruments often used in clinical trials (i.e. the SF36 and EuroQol5D) -and disease specifi c outcome measures (i.e. Oswestry Disability Index [ODI], leg and back pain visual analogue scale [VAS]) in neuropathic patients with FBSS. METHODS: Multivariate hierarchical regression models to capture the longitudinal trend in the dependent variables (i.e. generic HRQoL), and to assess their relationship with patient baseline variables and clinical history. RESULTS: Generic HRQoL was univariately consistently associated with disease specifi c outcome measures: ODI (correlation coeffi cient: 0.462 to 0.638) and leg pain VAS (correlation coeffi cient: 0.165 to 0.436). In multilevel regression analysis, baseline HRQoL and ODI were found to be signifi cant predictors of generic HRQoL (all p 0.001). Leg pain was predictive of EuroQol5D and the SF36 physical component summary score (both p 0.001) but not of its mental component summary score (p 0.201). Baseline socio demographic characteristics (age and gender), clinical history (time since last back surgery and number of back surgeries), location of pain and intensity of back pain were not predictive of generic HRQoL (all p 0.10). CONCLUSIONS: Reduction in leg pain and functional disability is statistically signifi cantly associated with improvements in generic HRQoL. This is the fi rst study to investigate the longitudinal relationship between generic and disease specifi c HRQoL of neuropathic pain patients with FBSS, using multinational data.
PSY33 PROCESS MEASUREMENT AND CALCULATION IN IV-PCA AT UNIVERSITY HOSPITAL OULU FINLAND
Liwing J 1 , Rebmann I 2 , Idänpään-Heikkilä JJ 3 , Löthgren M g 1 , Rahkamo L 3 , Kraemer M 2 , Rautio P 4 , Salomäki T 5 1 Janssen-Cilag AB, Sollentuna, Sweden, 2 Siemens AG Healthcare Consulting, Erlangen, Germany, 3 Janssen-Cilag Oy, Espoo, Finland, 3 4 Medicres Oy, Oulu, Finland, 5 Oulu university hospital, Oulu, Finland OBJECTIVES: To describe and measure intravenous patient controlled analgesia (IV-PCA) processes in postoperative pain management in patients with moderate to severe pain in clinical practice that have undergone surgery at the University Hospital Oulu Finland. METHODS: A model was designed and visualized via Swimlane notation. Sub process levels were defi ned as "education", "purchasing/depreciation/maintenance", "procurement", "supply", "application" and "disposal". Based on these sub process levels, data was collected by two research methods, interviews and measurement forms including patient and staff satisfaction questionnaires. RESULTS: Twelve members of Oulu University Hospital personnel with different responsibilities were interviewed to defi ne the roles and activities involved in the entire IV-PCA process. Ten different roles were defi ned with 151 different activities. The involved roles and the duration of each activity in the sub process levels "supply", "application" and "disposal" were measured from 108 consecutive patients with eight different surgery types. The most common surgery types were back surgery and gynecological laparoscopy. The average duration of IV-PCA use per patient was 41 hours and 39 minutes. The staff spent on average 132 minutes in IV-PCA related activities, of which the nurse spent 91%. The average cost, including material and staff, for 24-hour usage of IV-PCA was €122. The patients found the IV-PCA system easy to operate but hindered them in mobility and they were not able to sleep unhindered. According to the staff the IV-PCA system operated error-free and reliably but hindered the mobilization of the patient. CONCLUSIONS: IV-PCA involves many different roles and activities and intertwined sub processes. Therefore the whole system is complex and resource demanding. Comparisons of the results from similar studies at other hospitals will be very useful when trying to optimize the process. , Kessler Index (K-6), and Patient Health Questionnaire (PHQ2). The K-6 assesses the person's non-specifi c psychological distress (higher value means severe mental disability) and the PHQ2 assesses the depression severity. PHQ2 score of 3 was used to screen asthma patient with depression. The impact of obesity on HRQOL was estimated using multivariable regression while controlling for patients' demographic, socio-economic, and co-morbidity variables. Data were analyzed using SAS and STATA. RESULTS: A total of 5339 asthma patients were identifi ed. Overall, HRQOL in obese patients were signifi cantly lower compared to those of normal weight patients (50.7 vs. 41.9 for PCS-12, 49.0 vs. 47.0 for MCS-12, 3.9 vs. 5.3 for K-6, 0.6 vs. 1.1 for PHQ-2). While controlling for the study variables, QOL were worse if patients were obese, older, female, or less educated, as well as have cardiovascular disease. Proportion of patients with PHQ2 score 3 were 10.3% in normal weight and 19.7% in obese patients. CONCLUSIONS: Obesity signifi cantly deteriorates quality of life including both physical and mental components in asthma patients. The national health promotion to control weight needs to be emphasized to increase the benefi cial effects of HRQL in asthma patients. Patients with failed back surgery syndrome (FBSS) and chronic neuropathic pain experience levels of health-related quality of life (HRQoL) that are considerably lower than those reported in other areas of chronic pain. Interventions aimed at reducing pain in FBSS patients are expected to bring considerable HRQoL improvements. Using data from the multinational PROCESS trial, we investigated the longitudinal relationship between generic HRQoL -assessed using two instruments often used in clinical trials (i.e. the SF36 and EuroQol5D) -and disease specifi c outcome measures (i.e. Oswestry Disability Index [ODI], leg and back pain visual analogue scale [VAS] ) in neuropathic patients with FBSS. METHODS: Multivariate hierarchical regression models to capture the longitudinal trend in the dependent variables (i.e. generic HRQoL), and to assess their relationship with patient baseline variables and clinical history. RESULTS: Generic HRQoL was univariately consistently associated with disease specifi c outcome measures: ODI (correlation coeffi cient: 0.462 to 0.638) and leg pain VAS (correlation coeffi cient: 0.165 to 0.436). In multilevel regression analysis, baseline HRQoL and ODI were found to be signifi cant predictors of generic HRQoL (all p 0.001). Leg pain was predictive of EuroQol5D and the SF36 physical component summary score (both p 0.001) but not of its mental component summary score (p 0.201). Baseline socio demographic characteristics (age and gender), clinical history (time since last back surgery and number of back surgeries), location of pain and intensity of back pain were not predictive of generic HRQoL (all p 0.10). CONCLUSIONS: Reduction in leg pain and functional disability is statistically signifi cantly associated with improvements in generic HRQoL. This is the fi rst study to investigate the longitudinal relationship between generic and disease specifi c HRQoL of neuropathic pain patients with FBSS, using multinational data.
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PSY35 THE RELATIONSHIP BETWEEN QUALITY OF LIFE, DISABILITY AND PAIN IN PATIENTS WITH FAILED BACK SURGERY SYNDROME
PSY36 THE HEALTH BURDEN OF NEUROPATHIC PAIN: A SYSTEMATIC REVIEW AND META-ANALYSIS OF HEALTH UTILITIES
Taylor RS 1 , Jensen M 2 , Doth AH 3 1 Universities of Exeter and Plymouth, Exeter, UK, 2 University of Washington School of Medicine, Seattle, WA, USA, 3 Medtronic Neuromodulation, Minneapolis, MN, USA Patients with neuropathic pain (NeuP) report poorer health-related quality of life (HRQoL) and incur higher health care costs than non neuropathic pain patients. Although the impact of NeuP on HRQoL has been the subject of previous reviews, the health utility associated with NeuP remains unclear. Knowledge regarding this association is needed, as it impacts economic evaluations of treatments for NeuP. OBJECTIVES: To undertake a systematic review and meta-analysis of published health utility values of patients with NeuP. METHODS: A detailed search of bibliographic medical databases (Medline, Embase, Cochrane Library) and specialist economic databases (NHS Centre for Reviews and Dissemination Economic Evaluation Database and Health Economics Evaluation Database) was undertaken (to September 2008). Reference lists of retrieved reports were also searched. Studies reporting utility single-index measures (preference based) in NeuP were included. Random effects meta-analysis was used to pool utility estimate across studies. The association of utilities and a number of pre-defi ned factors (NeuP indication, patient age, sex, duration and severity of pain and method of utility scoring) was examined using meta-regression. RESULTS: Twenty three studies reporting utility values in patients with NeuP were included, of which 11 were randomised trials that also reported the treatment change in utility. The weighted pooled mean utility score across the studies was 0.48 (95% CI: 0.44 to 0.53). There was evidence of substantial statistical heterogeneity across studies (P 0.0001). Although we found little evidence of variation in utility across patient characteristics or NeuP indication, increasing pain severity was found to be strongly associated with a reduction in utility. CONCLUSIONS: This study confi rms that NeuP patients experience low utilities and therefore poor quality of life. Pain severity appears to be a major driver of the negative health impact of NeuP and therefore needs to be considered in future economic evaluations of interventions for this patient population. 4 University of Utah, Salt Lake City, UT, USA OBJECTIVES: It is known the obesity increases in general population of the Republic of Serbia; the average value of the BMI in adults was 26.0 and 26.7 (2000 vs. 2006 ). Proposed study, conducted in 2007 had been focused on the dietary behavior and consumption of dietary supplement among the adults, as well as gender differences. METHODS: An observational, prospective study was performed among adults (both, males and females) in form of short questionnaire. The questionnaire included 14 topics covering the following concepts: personal data, usage and knowledge of dietary supplements and other way for weight loss. A total of 993 adults were included, 224 (22.56%) who used dietary supplements and 769 (77.44%) who didn't. The study was conducted in public pharmacy setting of three cities of Serbia (Belgrade, Novi Sad and Nis). RESULTS: The mean value of BMI for male was 26.25 and female 23.79, difference was statistically signifi cant. It is showed the BMI values were higher in all age groups of males compared to those of females, except in 60 years of age and older. In both cohorts groups the obesity became clinically signifi cant in population older than 40 years of age. Of 224 examinees, only 10% used dietary supplements every day and 12% used it sparingly. The main purpose of their usage is improvement of physical appearance (49%), disease prevention (41%) and existing disease (10%). Previously to dietary supplements use the examinees tried to lose weight through diet (35%), exercise (24%), lower food portions without any diet (23%), more water consumption (11%), and 7% did not take any action. CONCLUSIONS: We conclude the outcomes of the proposed study have showed the somewhat awareness and behavior toward obesity in domain of disease prevention and gender difference (males have higher BMI values) exist in the general population of the Republic of Serbia. Obesity is a worldwide pandemic with serious health implications including increased risk of cardiovascular disease and type 2 diabetes. Unfortunately, attempts to develop antiobesity medications have had mixed results due to poor tolerability and adverse events. Furthermore, the absence of a well developed patient reported outcome (PRO) measure assessing the impact of antiobesity medication on functioning and well-being has limited our understanding of treatment impact. This study validated the Treatment Related Impact Measure (TRIM)-Weight, a diseasespecifi c PRO measure for assessing these relevant impacts. METHODS: The 43-item TRIM-Weight, developed and debriefed in a previous study according to the 2006 draft FDA guidelines, was validated in this web-based survey in 4 countries (United States, UK, Australia, Canada) for measurement structure and psychometric properties to assess factor structure, reliability, validity for the total score and for each domain. RESULTS: Two hundred eight respondents completed the survey. Twenty-one of the 43 items were omitted due to redundancy with other items, ceiling effects, poor factor loadings, or poor conceptual fi t resulting in a 22 item measure. A fi ve-factor structure was achieved with domains of Daily Life, Weight Management, Treatment Burden, Experience of Side Effects, and Psychological Health. Internal consistency coeffi cients of the total score and each subscale ranged between 0.71 and 0.94 and test-retest reliability ranged from 0.75 to 0.86. All pre-specifi ed hypotheses for convergent and the majority for known-groups validity were met. The completion time was estimated to be 3.38 (SD 2.49) minutes. CONCLUSIONS: The development of the TRIMWeight was conducted according to well-defi ned scientifi c principles. The total score, as well as each domain subscale, are a brief, conceptually sound, rigorously developed PRO measure with strong evidence supporting the psychometric properties. Use of the TRIM-Weight in both clinical and research settings can facilitate development of patient-centered treatments resulting in a greater adherence, tolerability, and treatment effi cacy.
PSY37 THE OBESITY TRENDS IN GENERAL POPULATION OF THE REPUBLIC OF SERBIA
PSY38 VALIDATION OF THE TREATMENT RELATED IMPACT MEASURE FOR PRESCRIPTION WEIGHT LOSS MEDICATION IN OBESITY; TRIM-WEIGHT
PSY39 LINGUISTIC VALIDATION OF THE LUPUS QOL QUESTIONNAIRE INTO 13 LANGUAGES
Handa ML 1 , McKown S 1 , Gawlicki M 2 1 Corporate Translations, Inc, Chicago, IL, USA, 2 Corporate Translations, Inc, East Hartford, CT, USA OBJECTIVES: Patients with Systemic Lupus Erythematosus (SLE) have shown significantly improved survival rates, causing researchers and physicians alike to become increasingly interested in patients' health-related quality of life. A variety of questionnaires exist to assess this measure; however, the Lupus Quality of Life Questionnaire (LupusQoL) is the only disease-specifi c questionnaire. Since this questionnaire was only recently developed and psychometrically validated, it has yet to be linguistically validated for use across diverse cultures and languages. The objective of this study was to create and validate thirteen translations of the LupusQoL. METHODS: To evaluate the linguistic validity of harmonized translations of the LupusQoL, bilingual (target language and English) interviewers cognitively debriefed subjects to assess their ability to paraphrase and understand the instructions, questions and responses within each translation. A total of thirteen translations were debriefed as part of this research [Chinese (Taiwan), Dutch (Belgium), English (US/Canada), French (Belgium/France, Canada), Greek (Greece), Hungarian (Hungary), Italian (Italy), Portuguese (Brazil), Spanish (Argentina/Chile, Mexico, US/Canada), Swedish (Sweden)]. The results of the debriefi ngs were compared on the basis of comprehension and number of suggested changes. RESULTS: Seventy-three subjects were interviewed, between 5 and 7 subjects for each of the 13 languages tested. Subjects ranged in age from 19-76 years, with a mean age of 44.2 years and were stratifi ed by educational level, including participants both with and without a high school degree. The overall item comprehension rate for the LupusQoL was 99.5%. Intra-item and intra-language comprehension rates were also established. All items had a comprehension rate of greater than 91.8%, while most had 100%; all countries had at least a 98.1% rate. CONCLUSIONS: The translations of the instrument in this study demonstrated a high level of overall linguistic validity. This research will facilitate inter-country comparisons of Systemic Lupus Erythematosus and the pooling of data in multi-country studies. Congenital hemophilia (CH) results from a defi ciency of factors VIII or IX, and is associated with bleeding. Treatment can be complicated by potential development of alloantibodies (inhibitors), which can result in more diffi cult to control bleeding episodes and decreased quality of life (QoL) for the patient and family. Prior studies have only assessed QoL at the start and end of a treatment interval. This study reports the preliminary feasibility of evaluating the yet unknown day-to-day QoL variability in CH patients with inhibitors. METHODS: Patients with CH with inhibitors or their caregivers were asked to participate in a 90-day diary study that captured all bleed treatments, daily activities, QoL (modifi ed EQ-5D health state classifi er, health and pain visual analog scales (VAS)), family anxiety/stress, and activity changes. Patients/caregivers kept primary diaries on paper with optional internet-based data entry. Graphical and quantitative representations were used to assess feasibility and discriminative validity of daily QoL assessment and impact of bleeds on QoL. RESULTS: Patients who fully completed the diary study (n 3) each experienced 4-5 bleeds during diary days (n 273 total days). QoL patterns were distinctly different across patients (VAS 1-way ANOVA, p 0.001). VAS (Health, Pain) appeared more sensitive to daily variability than EQ-5D dimensions. Health and pain VAS and self-care, usual activities, pain/discomfort, anxiety/depression dimensions discriminated between combined bleed and non-bleed days (p 0.05). Family anxiety/ stress and activity changes were more pronounced in the patients with variable baseline QoL suggesting concern over impending bleeds. CONCLUSIONS: Preliminary evidence suggests the VAS a is discriminative tool for bleeds for some patients, but a large study will help to further validate the measure at the group level. Daily QoL assessments may be valuable in assessing treatment interventions in patients with CH with inhibitors. Continuation of the study to completion with the planned 35 patients is warranted.
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